Table 2 Characteristics of novel chlorothiazide and furosemide exposures (n = 137).
Characteristics | Chlorothiazide | Furosemide | p-value |
|---|---|---|---|
Respiratory support at diuretic exposure, No. (%) | 0.24 | ||
Non-invasive CPAP | 6 (30) | 27 (23) | |
Non-invasive bi-level support | 1 (5) | 1 (1) | |
Conventional mechanical ventilation | 13 (65) | 78 (67) | |
High frequency ventilation | 0 (0) | 11 (9) | |
PMA at diuretic exposure (weeks), mean (SD) | 46 (7) | 44 (7) | 0.16 |
High diuretic dose exposure, No. (%) | 6 (30) | 35 (30) | 0.99 |
Route of diuretic exposure, No. (%) | < 0.001 | ||
Oral, nasogastric, or gastrostomy tube | 14 (70) | 24 (20) | |
Nasoduodenal | 4 (20) | 17 (15) | |
Intravenous | 2 (10) | 76 (65) | |
Doses between initiation and post-exposure lab, No. (%) | < 0.001 | ||
1 | 0 (0) | 61 (52) | |
2 | 5 (25) | 31 (27) | |
3 | 2 (10) | 8 (7) | |
4 or greater | 13 (65) | 17 (14) | |
Exposure to TPN during exposure, No. (%) | 4 (20) | 52 (44) | 0.04 |
Enteral NaCl supplementation at exposure, No. (%) | 1 (5) | 11 (9) | 0.52 |
Enteral KCl supplementation at exposure, No. (%) | 0 (0) | 4 (3) | 0.40 |
Na supplementation increase during exposure, No. (%) | 0 (0) | 8 (7) | 0.23 |
K supplementation increase during exposure, No. (%) | 1 (5) | 14 (12) | 0.36 |
Cl supplementation increase during exposure, No. (%) | 1 (5) | 17 (14) | 0.24 |
Exposure and follow-up lab time difference (hours), mean (SD) | 43.8 (22.8) | 54.4(42.0) | 0.28 |
Baseline and follow-up lab time difference (hours), mean (SD) | 156 (83) | 115 (86) | 0.05 |
Hydrocortisone during exposure, No. (%) | 0 (0) | 28 (24) | 0.01 |
Dexamethasone during exposure, No. (%) | 2 (10) | 5 (4) | 0.28 |
Dopamine during exposure, No. (%) | 0 (0) | 3 (3) | 0.47 |
